Verified by AISci
Public source attached
Source status for this paper in the current AISci reviewed snapshot.
- Primary source
- ClinicalTrials.gov
- Correction status
- none
- Evidence coverage
- 1 sources / 1 publishers
- Last metadata check
- Jul 19, 2026
clinical trialBiotech
A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B) (NCT05319730)
Source-permitted summary
A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B) | Phase: PHASE1 | Conditions: Esophageal Squamous Cell Carcinoma
SourceClinicalTrials.govAI Reading Notes
Core signal
Structured notes generated from source-linked AISci metadata. Treat them as a reading aid, not a substitute for the paper.
- Core signal
- A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B) | Phase: PHASE1 | Conditions: Esophageal Squamous Cell Carcinoma
- Field context
- Protein and Drug Design
- People and labs
- Not stated in the reviewed source.
- Why it matters
- Clinical trial registry updates are translation signals, not commercialization claims by themselves.
- Limits to check
- ClinicalTrials.gov status does not prove product approval, licensing, revenue, or market adoption.
Research Workflow
Research Workflow
Recommended next steps for turning this signal into research action.
- Read original source
- Check DOI/OpenAlex
- Open relationship graph
- Review people and labs: Not stated in the reviewed source.
- Open linked event for AISci context
- Prepare journal-club PPT: AISci action coming next
- Plan replication checks: AISci action coming next
Publication facts
- Type
- clinical trialSourceClinicalTrials.gov
- Date
- Jun 26, 2026SourceClinicalTrials.gov
- Venue
- ClinicalTrials.govSourceClinicalTrials.gov
- Open access
- openSourceClinicalTrials.gov
External IDs
Author order
No reviewed author edge is attached to this output.
Organizations
No source-confirmed author affiliation is attached.
Related events
Topics
Relationship evidence
Protein and Drug Design
Controlled AISci Stage A topic for Protein and Drug Design.
Merck Sharp & Dohme LLC
Organization linked by public source evidence.
A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
Clinical/translation signal: A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
Timeline
- clinical trialA Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)